Skye Bioscience Inc.
SKYE | NASDAQ
$1.75
-$0.03 (-1.69%)
Sep 22, 2026, 12:15 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 723.35K | n/a | n/a | n/a | n/a | 1.87K |
Gross Profit | -723.35K | n/a | n/a | n/a | n/a | -1.87K |
Operating Income | -58.16M | -30.19M | -34.74M | -18.31M | -7.85M | -6.29M |
Interest Income | 1.88M | 3.26M | 99.97K | 19.01K | 3 | 29 |
Pretax Income | -55.92M | -26.56M | -37.64M | -19.47M | -8.52M | -6.56M |
Net Income | -55.92M | -26.57M | -37.64M | -19.48M | -8.52M | -6.56M |
Selling & General & Admin | 15.8M | 17.73M | 7.85M | 6.09M | 4.92M | 4.35M |
Research & Development | 42.36M | 18.7M | 5.82M | 6.01M | 2.93M | 1.94M |
Other Expenses | -723.35K | -6.23M | 21.06M | 6.21M | n/a | n/a |
Operating Expenses | 57.44M | 30.19M | 34.74M | 18.31M | 7.85M | 6.29M |
Interest Expense | n/a | 967.6K | 906.27K | 663.77K | 767.51K | 706.39K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 58.16M | 30.19M | 34.74M | 18.31M | 7.85M | 6.29M |
Income Tax Expense | 5.4K | 10.07K | 3.6K | 6.74K | 2.1K | 1.6K |
Shares Outstanding (Basic) | 4.96M | 4.56M | 875.75K | 277.64K | 203.3K | 115.37K |
Shares Outstanding (Diluted) | 4.96M | 4.56M | 875.75K | 277.64K | 203.3K | 115.71K |
EPS (Basic) | -11.28 | -5.84 | -42.96 | -70.16 | -40 | -56.88 |
EPS (Diluted) | -11.28 | -5.84 | -42.96 | -70.16 | -40 | -59.68 |
EBITDA | -55.2M | -25.29M | -36.62M | -18.7M | -7.72M | -5.85M |
EBIT | -55.92M | -25.59M | -36.74M | -18.81M | -7.75M | -5.85M |
Depreciation & Amortization | 723.35K | 298.64K | 124.25K | 115K | 34.13K | 1.87K |
Add to Watchlist
Select watchlists to add or remove SKYE